Metoclopramide In Children Research Articles

Seizure Mimics: Oculogyric Crisis Following Metoclopramide-Video

A 9-year-old girl who experienced a seizure disorder was referred to our hospital by a medical practitioner. She presented with recurrent episodes of upward deviation of eyes with neck pain. She had taken tab metoclopramide 10 mg every 8 hours one day before for gastroenteritis. She was aware but unable to voluntarily control the attacks. On examination, she had sustained conjugate upward and lateral deviation of the eyes (oculogyric crisis), without loss of consciousness ([Fig. 1] [Video 1]). Symptoms disappeared rapidly following administration of IV promethazine 0.5 mg/kg slowly, and she remained well during follow-up 1 week later. Oculogyric crisis (OGC) is characterized by a prolonged involuntary upward deviation of the eyes. These episodes generally last for minutes, but can range from seconds to hours. Etiology includes drug-induced reactions, hereditary and sporadic movement disorders, and focal brain zdlesions. The majority of OGC cases occurred as adverse effects of neuroleptics and antiemetics. OGC usually disappears within 24 to 48 hours of drug withdrawal. Administration of anticholinergics (benztropine) or antihistamines (diphenhydramine) can alleviate OGC within minutes. The incidence of metoclopramide-induced acute dystonias is 0.2% with female preponderance.[1] A systematic review and meta-analysis revealed that the most common adverse effects following metoclopramide in children were extrapyramidal symptoms (9%), diarrhea (6%), and sedation (6%).[2] Ozel et al reported acute dystonic reaction due to metoclopramide in a 20-year-old female, which was misinterpreted as conversion disorder and seizure.[3] Acute dystonic reactions due to metoclopramide can be confused with conversion disorders, seizures and encephalitis.[1] [3] Our patient was also referred to our center by a medical practitioner on account of a presumed diagnosis of seizure disorder.

The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

Metoclopramide is recommended for adults with breakthrough or refractory chemotherapy-induced nausea and vomiting (CINV) and for CINV prophylaxis in children. The drug regulatory agencies of Canada and the EU have revised the labelling of metoclopramide to contraindicate its use in children aged <1 year and to caution against its use in children aged <5 years and its duration of use beyond 5 days. This review describes the safety of metoclopramide in children when given for any indication. We conducted electronic searches in MEDLINE and Embase as of 9 March 2015. All studies in English reporting adverse effects associated with the use of metoclopramide in children (aged ≤18 years) were included. Adverse effects that had a cumulative incidence of at least 1% and were reported in prospective studies were synthesized. A total of 108 (57 prospective) studies involving 2699 patients (2745 metoclopramide courses) were included. The most common adverse effects reported in prospective studies of metoclopramide in children were extrapyramidal symptoms (EPS; 9%, 95% confidence interval [CI] 5-17), diarrhea (6%, 95% CI 4-9), and sedation (multiple-dose studies: 6%, 95% CI 3-12). Dysrhythmia, respiratory distress/arrest, neuroleptic malignant syndrome, and tardive dyskinesia were rarely associated with metoclopramide use. The definitions of adverse effects reported in the included studies were heterogeneous, and the risk of bias in most studies was moderate. The most commonly reported adverse effects associated with the use of metoclopramide in children-EPS, diarrhea, and sedation-were reversible and of no long-term significance. Adverse effects that were life threatening or slow to resolve were rarely associated with its use in children.

Retraction Note to: Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery

Further to the Expression of Concern posted online on March 13th, 2012, it is with considerable regret that the Canadian Journal of Anesthesia hereby retracts the above-cited article by Dr. Yoshitaka Fujii as a result of:(1) overwhelming evidence of fabrication relating to the fact that the distributions of many variables reported by Dr. Fujii in these studies are exceedingly unlikely; and the inability of Dr. Fujii’s institution to attest to the integrity of the study and/or the data conducted under its auspices, as set out in the Joint Editors-in-Chief Request for Determination of April 9, 2012. We extend our sincere appreciation to Toride Kyodo General Hospital for their review of the status of Dr. Fujii’s research and to the investigating committee for their review of his research findings.

Adjunctive Atropine Versus Metoclopramide: Can We Reduce Ketamine‐associated Vomiting in Young Children? A Prospective, Randomized, Open, Controlled Study

Pediatric procedural sedation and analgesia (PPSA) with ketamine administration occurs commonly in the emergency department (ED). Although ketamine-associated vomiting (KAV) is a less serious complication of ketamine administration, it seems to be cumbersome and not uncommon. The authors evaluated the incidence of KAV and the prophylactic effect of adjunctive atropine and metoclopramide in children receiving ketamine sedation in the ED setting. This prospective, randomized, open, controlled study was conducted in children receiving ketamine sedation in the ED of a university-affiliated, tertiary hospital with 85,000 ED visits, including 32,000 pediatric patients from October 2010 to September 2011. The primary outcome was a measure of the incidence of KAV in the ED and after discharge according to the adjunctive drug administered. Secondary outcome measures included the time to resumption of a normal diet after ketamine sedation. Of the 1,883 children administered ketamine for primary wound repair during the study period, a convenience sample of 338 patients aged 4 months to 5 years was enrolled. The incidences of KAV were 28.4% in the ketamine alone group, 27.9% in the ketamine with adjunctive atropine group, and 31.2% in the ketamine with adjunctive metoclopramide group (p = 0.86). The vomiting rate after discharge was 9.2% in the ketamine alone group. The nothing-by-mouth (NPO) status before sedation did not influence the incidence of KAV in any of the groups. Mean times to resumption of normal diet after ketamine administration were 7 hours 59 minutes in the ketamine alone group, 7 hours 35 minutes in the ketamine with atropine group, and 8 hours 1 minute in the ketamine with metoclopramide group (p = 0.64). In this study, a high rate (28.4%) of KAV was observed, consistent with prior reports using the intramuscular (IM) route. However, the authors were unable to reduce KAV using adjunctive atropine or metoclopramide. Parents or caregivers should be given more detailed discharge instructions about vomiting and diet considering the relatively long time to resuming a normal diet after ketamine sedation and the fact that KAV often occurred after ED discharge.

Antiemetic activity of ginger in childrenreceiving cancer chemotherapy

Objective: To evaluate the antiemetic effect of ginger versus metoclopramide in children receiving cancer chemotherapy. Methods: A sample of 50 patients aged 6 – 14 years attending the Haematooncology unit in Ibn Al – Atheer Children's Teaching Hospital in Mosul city and receiving chemotherapy for their malignancies were included. They were randomly subdivided into 2 groups and received different types of treatment including ginger and metoclopramide. Results: The study showed that cancer was more common in female than in male with male to female ratio 0.85/1. Acute lymphoblastic leukemia was the most common type of cancer and constituted 60% of the cases and it revealed that response rate was higher in those treated by ginger compared to metoclopramide (72% and 32% respectively); response was found to be higher in males than in females (86.6% and 50% respectively). Conclusions: Nausea and vomiting are common problems in children receiving chemotherapy. Ginger (Zingiber officinale) appears to be promising in controlling these problems.

Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies

Metoclopramide has been used for almost 40 yr to prevent postoperative nausea and vomiting (PONV). We have reviewed the efficacy and safety of metoclopramide for the prevention of PONV. A systematic search (MEDLINE, EMBASE, manufacturers' databases, hand searching, bibliographies, all languages, up to June 1998) was performed for full reports of randomized comparisons of metoclopramide with placebo in surgical patients. Relevant end-points were prevention of early PONV (within 6 h after operation), late PONV (48 h) and adverse effects. Combined data were analysed using relative benefit/risk and number-needed-to-treat/harm. In 66 studies, 3260 patients received 18 different regimens of metoclopramide, and 3006 controls received placebo or no treatment. There was no evidence of dose-responsiveness with oral, i.m., intranasal or i.v. metoclopramide in children and adults. In adults, the best documented regimen was 10 mg i.v. There was no significant anti-nausea effect. The numbers-needed-to-treat to prevent early and late vomiting were 9.1 (95% confidence intervals 5.5-27) and 10 (6-41), respectively. In children, the best documented regimen was 0.25 mg kg-1 i.v. The number-needed-to-treat to prevent early vomiting was 5.8 (3.9-11). There was no significant late anti-vomiting effect. Minor drug-related adverse effects (sedation, dizziness, drowsiness) were not significantly associated with metoclopramide. There was one adult who experienced extrapyramidal symptoms with metoclopramide.

A Systematic Review of the Antiemetic Efficacy of Prophylactic Ondansetron compared with Droperidol and with Metoclopramide in Children

AbstractObjective: To determine the pooled relative risk (RR) of prophylactic ondansetron relative to droperidol and relative to metoclopramide for prevention of post-operative (p.o.) vomiting in children.Design: Meta-analysis of published randomised trials of p.o. emesis.Study Selection: Of 22 articles reviewed in detail by the three authors, 19 met the eligibility criteria. The meta-analysis of ondansetron versus droperidol included 13 studies. The metoclopramide meta-analysis included 8 studies.Main Outcome: P.O. vomiting over a 24-hour period.Results: There were consistent statistically significant benefits of ondansetron compared with droperidol (pooled RR 0.67, 95% confidence interval 0.49-0.90, p=0.0092) and with metoclopramide (0.56, 0.44-0.71, p<.001). There was no evidence of heterogeneity among either the droperidol studies (p for homogeneity=0.17) or the metoclopramide studies (p=0.25). There was no apparent effect of drug dose, study quality or type of outcome (vomiting or nausea) nor were th...

Neurological Side Effects Associated with Unnecessary Use of Metoclopramide in Children

Neurological Side Effects Associated with Unnecessary Use of Metoclopramide in Children

Extrapyramidal Reactions Caused by Metoclopramide in Children

Extrapyramidal Reactions Caused by Metoclopramide in Children

Dystonic reactions and the pharmacokinetics of metoclopramide in children.

The pharmacokinetics of metoclopramide have been studied in nine children receiving the drug as prophylaxis for cytotoxic induced vomiting. Plasma concentrations of metoclopramide have also been studied in three children with dystonic reactions to the drug. The pharmacokinetics in children were similar to those reported in healthy adults. There was no difference in the plasma concentration of metoclopramide of children with dystonia when compared to those without this adverse effect. Kinetic differences in childhood do not explain the occurrence of dystonia, which in the individual appears to be related to factors other than plasma drug concentrations.